FindTrial
Sign In

ABT-348

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott)

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAdvanced Solid TumorsB-cell Chronic Lymphocytic LeukemiaChronic Myelogenous LeukemiaMyelodysplasia

Phase 1

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
CompletedNCT01110486
AbbVie (prior sponsor, Abbott)Advanced Solid Tumors
Start: 2010-03-31End: 2013-09-30Updated: 2013-11-06
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
CompletedNCT01110473
AbbVie (prior sponsor, Abbott)Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia +2
Start: 2010-04-30End: 2013-06-30Updated: 2017-11-20

Related Papers

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
British Journal of Cancer2018-03-1522 citations
Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib.
Journal of Clinical Oncology2017-05-201 citations